Staff Publications

Staff Publications

  • external user (warningwarning)
  • Log in as
  • language uk
  • About

    'Staff publications' is the digital repository of Wageningen University & Research

    'Staff publications' contains references to publications authored by Wageningen University staff from 1976 onward.

    Publications authored by the staff of the Research Institutes are available from 1995 onwards.

    Full text documents are added when available. The database is updated daily and currently holds about 240,000 items, of which 72,000 in open access.

    We have a manual that explains all the features 

Record number 541020
Title Therapeutic immunization against glioblastoma
Author(s) Schijns, Virgil E.J.C.; Pretto, Chrystel; Strik, Anna M.; Gloudemans-Rijkers, Rianne; Deviller, Laurent; Pierre, Denis; Chung, Jinah; Dandekar, Manisha; Carrillo, Jose A.; Kong, Xiao Tang; Fu, Beverly D.; Hsu, Frank P.K.; Hofman, Florence M.; Chen, Thomas C.; Zidovetzki, Raphael; Bota, Daniela A.; Stathopoulos, Apostolos
Source International Journal of Molecular Sciences 19 (2018)9. - ISSN 1661-6596
DOI https://doi.org/10.3390/ijms19092540
Department(s) Cell Biology and Immunology
Publication type Refereed Article in a scientific journal
Publication year 2018
Keyword(s) Allogenic - Autologous - Brain tumor - Glioma tumor - Immunotherapy - Therapeutic vaccine
Abstract Glioblastoma is the most common form of brain cancer in adults that produces severe damage to the brain leading to a very poor survival prognosis. The standard of care for glioblastoma is usually surgery, as well as radiotherapy followed by systemic temozolomide chemotherapy, resulting in a median survival time of about 12 to 15 months. Despite these therapeutic efforts, the tumor returns in the vast majority of patients. When relapsing, statistics suggest an imminent death dependent on the size of the tumor, the Karnofsky Performance Status, and the tumor localization. Following the standard of care, the administration of Bevacizumab, inhibiting the growth of the tumor vasculature, is an approved medicinal treatment option approved in the United States, but not in the European Union, as well as the recently approved alternating electric fields (AEFs) generator NovoTTF/Optune. However, it is clear that regardless of the current treatment regimens, glioma patients continue to have dismal prognosis and novel treatments are urgently needed. Here, we describe different approaches of recently developed therapeutic glioma brain cancer vaccines, which stimulate the patient’s immune system to recognize tumor-associated antigens (TAA) on cancer cells, aiming to instruct the immune system to eventually attack and destroy the brain tumor cells, with minimal bystander damage to normal brain cells. These distinct immunotherapies may target particular glioma TAAs which are molecularly defined, but they may also target broad patient-derived tumor antigen preparations intentionally evoking a very broad polyclonal antitumor immune stimulation.
Comments
There are no comments yet. You can post the first one!
Post a comment
 
Please log in to use this service. Login as Wageningen University & Research user or guest user in upper right hand corner of this page.